格隆汇7月23日丨药明合联(02268.HK)发布公告,截至2025年6月30日止六个月,预期集团录得较上年同期财务业绩:(1)收入增长超过60%;(2)经调整净利润(不含利息收入及开支)增长超过67%;及(3)净利润增长超过50%。公司认为,有关预期增长主要归因于以下因素:(1)抗体偶联药物(ADC)及更广泛生物偶联药物行业的下游需求持续旺盛;(2)集团通过稳固的领先地位及竞争优势,获得生物偶联...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.